Comparison of our series with two other large series of patients with pneumothorax
| Udwadia et al | Martinelli et al 10 | Miro et al 11 | |
|---|---|---|---|
| Setting | 3 Mumbai ICUs | 16 UK hospitals | 61 Spanish emergency departments |
| N | 1,324 critical COVID-19 patients | Case series of 71 patients | 71,904 all COVID-19 patients |
| Incidence | 42/1,324 = 3.17% | NA | 40/71,904 = 0.56% |
| Age | 60 (39–83) years | 21–80 years | 66 (47–74) years |
| Male | 37/42 (88.09%) | 57/71 (80%) | 29/40 (72.5%) |
| Prior lung disease | 5/42 (12%) | 28/71 (39.4%) | 12/40 (30%) |
| Ventilator-associated alveolar leak | Ventilator-associated 28/42 (67%) | Possibly ventilator-associated 38/61 (62%) | NA |
| Pneumothorax alone | 18/42 (43%) | 54/71 (76%) | 34/40 (85%) |
| Pneumomediastinium alone | 16/42 (38%) | 11/71 (15.5%) | NA |
| Pneumothorax + pneumomediastinum | 8/42 (19%) | 6/71 (8.5%) | 6/40 (15%) |
| Treatment | Observation 14/42 (33%) | Observation 26/71 (36%) | Pleural tube 29/40 (73%) |
| Pleural drain 28/42 (66%) | Pleural drain 43/71 (60%) | ||
| VATS 1/42 (2%) | Surgery 1/71 (1.4%) | ||
| Palliative 3/71 (4.2%) | |||
| Outcome | Death 31/42 (73%) | Pneumothorax 63.1±6.5% | NA |
| Pneumomediastinum 53.0±18.7% |